PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond

被引：261

作者：

Fattahi, Sadegh ^{[1
,2
,3
]}

Amjadi-Moheb, Fatemeh ^{[4
]}

Tabaripour, Reza ^{[5
]}

Ashrafi, Gholam Hossein ^{[6
]}

Akhavan-Niaki, Haleh ^{[4
]}

机构：

[1] Babol Univ Med Sci, Student Res Comm, Babol, Iran

[2] Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol, Iran

[3] Pasteur Inst, North Res Ctr, Amol, Iran

[4] Babol Univ Med Sci, Dept Genet, Fac Med, Babol, Iran

[5] Islamic Azad Univ, Dept Cellular & Mol Biol, Babol Branch, Babol, Iran

[6] Kingston Univ London, Sch Life Sci Pharm & Chem, SEC Fac, Canc Theme, London KT12EE, England

来源：

LIFE SCIENCES | 2020年 / 262卷

关键词：

PI3K/AKT/mTOR pathway; Epigenetic modulation; Gastric cancer; Chemoresistance; Non-coding RNAs; Targeted therapy; PROMOTES CISPLATIN RESISTANCE; INHIBITS CELL-PROLIFERATION; ABERRANT DNA METHYLATION; HUMAN OVARIAN-CANCER; NF-KAPPA-B; AKT INHIBITOR; UP-REGULATION; PHOSPHOINOSITIDE; 3-KINASES; MESENCHYMAL TRANSITION; SCAFFOLDING FUNCTION;

D O I：

10.1016/j.lfs.2020.118513

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

PI3K/AKT/mTOR pathway is one of the most important signaling pathways involved in normal cellular processes. Its aberrant activation modulates autophagy, epithelial-mesenchymal transition, apoptosis, chemoresistance, and metastasis in many human cancers. Emerging evidence demonstrates that some infections as well as epigenetic regulatory mechanisms can control PI3K/AKT/mTOR signaling pathway. In this review, we focused on the role of this pathway in gastric cancer development, prognosis, and metastasis, with an emphasis on epigenetic alterations including DNA methylation, histone modifications, and post-transcriptional modulations through non-coding RNAs fluctuations as well as H. pylori and Epstein-Barr virus infections. Finally, we reviewed different molecular targets and therapeutic agents in clinical trials as a potential strategy for gastric cancer treatment through the PI3K/AKT/mTOR pathway.

引用

页数：16

共 50 条

[31] Stability Analysis of the PI3K–Akt–mTOR Signaling Pathway
Sapega T.S.
Guria G.T.
Biophysics, 2020, 65 (2) : 259 - 267
[32] PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn JX Lee
Kiley Loh
Yoon-Sim Yap
Cancer Biology & Medicine, 2015, (04) : 342 - 354
[33] PI3K/Akt/mTOR inhibitors in breast cancer
Lee, Joycelyn J. X.
Loh, Kiley
Yap, Yoon-Sim
CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
[34] The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis
Ying, Jieer
Xu, Qi
Liu, Bixia
Zhang, Gu
Chen, Lei
Pan, Hongming
ONCOTARGETS AND THERAPY, 2015, 8 : 2427 - 2433
[35] The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis
Ying, J. E.
He, Q.
Sun, W. Y.
Xu, Q.
Li, D. C.
Liu, B. X.
Du, Y. A.
Cao, W. M.
Chen, L. Y.
Wu, W.
Chen, L.
Luo, C.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S463 - S464
[36] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
Bhatt, Aadra P.
Damania, Blossom
FRONTIERS IN IMMUNOLOGY, 2013, 3
[37] Inhibition of PI3K/Akt/mTOR Signaling by Natural Products
Huang, Shile
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 967 - 970
[38] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
Dimitrova, V.
Arcaro, A.
CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
[39] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Mazzoletti, M.
Broggini, M.
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
[40] PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn JX Lee
Kiley Loh
Yoon-Sim Yap
Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354

← 1 2 3 4 5 →